Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

47765results about "Immunological disorders" patented technology

Novel fused heterocyclic compound serving as CDK inhibitor and use thereof

Disclosed in the present invention is a novel fused heterocyclic compound having CDK target inhibitory activity. Specifically disclosed are a compound having a structure as shown in formula (I) and serving as a CDK target inhibitor, or a pharmaceutically acceptable salt, solvate, hydrate, isotopic substituent or isomer thereof.
Owner:MINDRANK AI LTD

Epinephrine spray formulations

Provided herein are epinephrine spray formulations. Also provided herein are methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatment.
Owner:BRYN PHARMA LLC

Treatment with anti-α4β7 antibody

Antibody formulations are described comprising a mixture of an anti-α4β7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo.
Owner:TAKEDA PHARMA CO LTD

Dry powder composition comprising long-chain RNA

The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-freeze drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry 10 powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.
Owner:CUREVAC SE

Dry powder composition comprising long-chain RNA

The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.
Owner:CUREVAC SE

Pan-ras inhibitor compound

The present invention relates to a compound as shown in formula (A) having a pan-RAS inhibitory effect, or an isotopic derivative or stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the compound, and the use of the compound of formula (A) in the prevention and / or treatment of cancers, tumors, inflammatory diseases, autoimmune diseases or immune-mediated diseases.
Owner:ADLAI NORTYE BIOPHARMA CO LTD

Compounds

A compound of formula (I) or a pharmaceutically acceptable salt or hydrate thereof wherein X-Y is -NHSO2- or -SO2NH-; R1 is H, CN or alkyl; R2 is selected from COOH and a tetrazolyl group; R3 is selected from H, Cl and alkyl; R4 is selected from H and halo; R5 is selected from H, alkyl, haloalkyl, SO2-alkyl, Cl, alkoxy, OH, CN, hydroxyalkyl, alkylthio, heteroaryl, cycloalkyl, heterocycloalkyl and haloalkoxy; R6 is H; R7 is selected from H, CN, haloalkyl, halo, SO2-alkyl, optionally substituted heteroaryl, SO2NR14R15, CONR10R11 and alkyl; R8 is selected from H, alkyl, haloalkyl and halo; R9 is H or halo; and R10, R11, R12, R14, and R15 are H or alkyl; R13 is selected from alkyl, halo, alkoxy, CN, haloalkyl and OH; and m is 0-3. The compounds of formula (I) modulate ERAP1 (endoplasmic reticulum aminopeptidase 1) and are for use in treating proliferative, immune or inflammatory disorders, particularly cancer or leukemia. The compounds of formula (I) stimulate a neo-antigen directed immune response in the subject. A method for producing an antigen-presenting cell which presents a neo-antigen using compounds of formula (I) is disclosed. An immunogenic composition comprising an antigen-presenting cell is also disclosed. Exemplified compounds include 4-cyclopropyl-3-(N-(2-(morpholin-3-yl)-5-(trifluoromethyl)phenyl)sulfamoyl)benzoic acid.
Owner:GREY WOLF THERAPEUTICS LTD

Methods of using dipivefrin

The disclosure provides a method for systemic delivery of a therapeutically effective amount of epinephrine to a subject comprising orally administering dipivefrin or a dipivefrin salt to the subject. The disclosure also includes a method of treatment of a disease amenable to treatment by in vivo delivery of systemic epinephrine comprising administering dipivefrin or a dipivefrin salt to a subject in need of in vivo delivery of systemic epinephrine. The disease can be a respiratory disorder, anaphylaxis, cancer, or a microbial infection. The disclosure also includes dipivefrin or dipivefrin HCl orally dissolving tablets.
Owner:INSIGNIS THERAPEUTICS INC

Pharmaceutical device for use in intranasal administration

Disclosed is a needle-free applicator that is suitable for administering a solid, amorphous, mono-particulate powder composition into a body cavity of a human patient, which cavity includes a mucosal surface, wherein the applicator comprises:(i) an opaque reservoir comprising said powder composition;(ii) an optional actuating means for generating a force upon actuation of the device by a user; and(iii)a dispensing means through which, following said actuation, said powder composition may be dispensed,wherein said powder composition comprises a pharmacologically-effective dosage amount of an adrenergic receptor modulator, or a pharmaceutically-acceptable salt thereof, encapsulated in an amorphous state along with a pharmaceutically-acceptable carrier material; andwhich powder composition is less than about 4% chemically degraded after storage for:(a) at least about 3 months at 40° C. and 75% relative humidity; and / or(b) at least about 18 months at below about 30° C.; and / or(c) at least about 18 hours at above about 1 million lux of UV light.
Owner:OREXO AB

Dry powder composition comprising long-chain RNA

The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.
Owner:CUREVAC SE

Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells

The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), compositions and reaction mixtures comprising the same, and methods of treatment using the same.
Owner:NOVARTIS AG +1

Pharmaceutical composition comprising adrenaline

ActiveUS20250041243A1Organic active ingredientsDigestive systemEpinephrine adrenalineBULK ACTIVE INGREDIENT
Disclosed is a pharmaceutically-acceptable composition in the form of a solid, amorphous, mono-particulate powder comprising a mixture of:a pharmacologically-effective dosage amount of an adrenergic receptor modulator, or a pharmaceutically-acceptable salt thereof; anda pharmaceutically-acceptable carrier material, which carrier material comprises a maltodextrin with a dextrose equivalent (DE) that is above 15.Compositions are suitable for transmucosal drug delivery, including nasal delivery, by which said compositions may be loaded into a single-use nasal applicator. Compositions are preferably made by way of spray drying and may further include a disaccharide, such as lactose or trehalose which, along with the active ingredient and maltodextrin, may be spray-dried together in combination. Compositions may further comprise one or more alkyl saccharides. Preferred alkyl saccharides include sucrose esters, such as sucrose monolaurate. Preferred adrenergic receptor modulators include epinephrine (adrenaline). The compositions are thus particularly useful in the treatment of allergic reactions, including anaphylaxis.
Owner:OREXO AB

Composition for treating il-6-related diseases

The present invention provides a pharmaceutical composition for treating IL-6-related diseases containing an IL-6 inhibitor as an active ingredient, wherein the pharmaceutical composition is routinely administered after a short-interval dosing period where the same dose as the routine dose is administered at a shorter interval than the routine dosing interval.
Owner:CHUGAI PHARMA CO LTD

A humanized nanoantibody against TNF-α and its application

The present invention belongs to the technical field of immunology, and in particular, relates to a humanized nanoantibody against TNF-α and its application. The present invention provides a humanized nanoantibody against TNF-α, and a recombinant humanized nanoantibody against TNF-α prepared by expressing the gene of the humanized nanoantibody against TNF-α. The humanized nanoantibody against TNF-α prepared by the present invention can specifically recognize the TNF-α antigen, thereby accurately targeting the inflammatory site, reducing nonspecific reactions, and improving the therapeutic effect.
Owner:DONGGUAN SOUTHEAST CENTRAL HOSPITAL (DONGGUAN SOUTHEAST TRADITIONAL CHINESE MEDICINE MEDICAL SERVICE CENTER DONGGUAN FIRST HOSPITAL AFFILIATED TO GUANGDONG MEDICAL UNIVERSITY)

Anti-TNF-alpha nano antibody and application thereof

The invention belongs to the technical field of immunology, and particularly relates to an anti-TNF-alpha nano antibody and application thereof. The invention provides an anti-TNF (Tumor Necrosis Factor)-alpha nano antibody. The anti-TNF-alpha recombinant nano antibody is prepared by performing gene expression on the anti-TNF-alpha nano antibody. The anti-TNF-alpha nano antibody prepared by the invention can specifically recognize a TNF-alpha antigen so as to accurately target an inflammation part, reduce non-specific reaction and improve the treatment effect.
Owner:GUANGDONG MEDICAL UNIV

A humanized nanobody against IL-6 and its recombinant vector and application

The present invention belongs to the technical field of immunology, and specifically relates to a humanized nano antibody against IL-6, and a recombinant vector and application thereof. The present invention analyzes the screened anti-IL-6 nano antibody 4G10 sequence, and for screening the heavy chain of IL-6, the anti-IL-6 nano antibody 4G10 includes a framework region FR and an antigenic determinant complementary CDR, and the CDR1, CDR2, and CDR3 regions of the screened anti-IL-6 nano antibody 4G10 sequence are transplanted into the humanized hs2dAb skeleton to obtain the humanized nano antibody 4G10 against IL-6 of the present application; the recombinant nano antibody expressed by the gene encoding the humanized nano antibody 4G10 against IL-6 and the His tag gene fusion can specifically recognize the IL-6 antigen, and can be applied to the molecular diagnosis of autoimmune diseases and tumors and the preparation of autoimmune diseases and anti-tumor drugs.
Owner:NINGXIA HUI AUTONOMOUS REGION PEOPLES HOSPITAL

Red ginseng fermentation liquor with high rare saponin content and high functional biological activity and preparation method of red ginseng fermentation liquor

The invention discloses red ginseng fermentation liquor with high rare saponin content and functional bioactivity and a preparation method thereof, and the preparation method comprises the following steps: mixing red ginseng powder with water to obtain red ginseng mixed liquor; cellulase is added into the red ginseng mixed solution for enzymolysis, and red ginseng enzymatic hydrolysate is obtained; or heating the red ginseng liquid, and performing hot water extraction to obtain a red ginseng extracting solution; heating the red ginseng extracting solution to be boiled, and after sterilization is finished, adding lactic acid bacteria powder for fermentation after the red ginseng solution is cooled, so as to obtain red ginseng fermentation liquor; and carrying out solid-liquid separation on the fermentation broth to obtain a fermentation supernatant, and sterilizing the red ginseng fermentation broth to obtain the sterilized red ginseng fermentation broth. According to the preparation method disclosed by the invention, the content of total saponins in the red ginseng fermentation liquor is increased, the variety and content of rare saponins can be increased, and in addition, the prepared red ginseng fermentation liquor has relatively high antioxidant activity, tyrosinase inhibition rate activity, leukoproteinase inhibition activity and hyaluronidase inhibition activity; wide application prospects and market potentials are realized.
Owner:XIAMEN YUANZHIDAO BIOTECHNOLOGY CO LTD

Salt forms of IRAK4 degraders

PCT designated stage expiredWO2025080300A1AntipyreticAnalgesicsDiseaseReceptor
The present disclosure relates generally to various salt forms and compositions thereof useful for the modulation of interleukin-1 receptor-associated kinase 4 ("IRAK4") via ubiquitination and / or degradation and uses of the same in the treatment various diseases.
Owner:KYMERA THERAPEUTICS INC

QS-21 composite adjuvant as well as preparation method and application thereof

The invention relates to the technical field of immunology, and discloses a QS-21 composite adjuvant as well as a preparation method and application thereof, and the QS-21 composite adjuvant comprises the following components in parts by weight: 0.1-0.5 part of QS-21; 4 to 6 parts of liposome; 0.05 to 0.1 part of CpG oligonucleotide; 0.1 to 0.3 part of a freeze-drying protective agent; 0.2 to 0.5 part of a stabilizing agent; 3 to 5 parts of propylene glycol; 1-2 parts of ethanol; 5-15 parts of an organic solvent chloroform; the liposome is prepared from the following components in parts by weight: 3 to 4 parts of phospholipid distearate; and 1-2 parts of amino lipid. By compounding the liposome carrier and the QS-21, adding the CpG oligonucleotide and optimizing the freeze-drying protective agent, the loading efficiency of the immunologic adjuvant, the immune effect stability and the restorability after freeze-drying are improved, and the durability and efficacy of immune response are enhanced.
Owner:BEIJING HUANUOTAI BIOMEDICAL TECH CO LTD

Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.
Owner:COMPASS PATHFINDER LTD

Treatment of lung cancer using a combination of an Anti-PD-1 antibody and another Anti-cancer agent

This disclosure provides a method for treating a subject afflicted with a lung cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an anti-cancer agent which is an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and (b) another anti-cancer agent. The other anti-cancer agent can be a platinum-based doublet chemotherapy, an EGFR-targeted tyrosine kinase inhibitor, an anti-VEGF antibody, an anti-Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) antibody, or any other therapy used to treat lung cancer in the art or disclosed herein.
Owner:BRISTOL MYERS SQUIBB CO